<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7252029\results\search\disease\results.xml">
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="long as the COVID-19 resource centre remains active. Abstract Coronavirus" exact="disease" post="2019 (SARS-CoV2) is an active global health threat for"/>
  <result pre="sought. Even though most people infected experience mild to moderate" exact="respiratory" post="symptoms and recover with supportive care, certain vulnerable hosts"/>
  <result pre="described in the context of cellular therapy. Specifically, Cytokine Release" exact="Syndrome" post="(CRS), Immune Reconstitution Inflammatory Syndrome (IRIS), and Secondary Hemophagocytic"/>
  <result pre="of cellular therapy. Specifically, Cytokine Release Syndrome (CRS), Immune Reconstitution" exact="Inflammatory" post="Syndrome (IRIS), and Secondary Hemophagocytic Lymphohistiocytosis (sHLH) all have"/>
  <result pre="cellular therapy. Specifically, Cytokine Release Syndrome (CRS), Immune Reconstitution Inflammatory" exact="Syndrome" post="(IRIS), and Secondary Hemophagocytic Lymphohistiocytosis (sHLH) all have clinical"/>
  <result pre="Cytokine Release Syndrome (CRS), Immune Reconstitution Inflammatory Syndrome (IRIS), and" exact="Secondary" post="Hemophagocytic Lymphohistiocytosis (sHLH) all have clinical and laboratory characteristics"/>
  <result pre="Release Syndrome (CRS), Immune Reconstitution Inflammatory Syndrome (IRIS), and Secondary" exact="Hemophagocytic Lymphohistiocytosis" post="(sHLH) all have clinical and laboratory characteristics in common"/>
  <result pre="CRS cytokine release HLH hyperimmune response immunotherapy IRIS SARS-CoV-2 Coronavirus" exact="disease" post="2019 (COVID-19) is an infectious illness caused by a"/>
  <result pre="response immunotherapy IRIS SARS-CoV-2 Coronavirus disease 2019 (COVID-19) is an" exact="infectious" post="illness caused by a novel betacoronavirus strain first recognized"/>
  <result pre="COVID-19, SARS-CoV2, is structurally related to viruses responsible for severe" exact="acute" post="respiratory syndrome (SARS-CoV) and Middle East respiratory syndrome coronavirus"/>
  <result pre="SARS-CoV2, is structurally related to viruses responsible for severe acute" exact="respiratory" post="syndrome (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV)."/>
  <result pre="is structurally related to viruses responsible for severe acute respiratory" exact="syndrome" post="(SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). These"/>
  <result pre="responsible for severe acute respiratory syndrome (SARS-CoV) and Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV). These coronavirus strains have been responsible"/>
  <result pre="for severe acute respiratory syndrome (SARS-CoV) and Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV). These coronavirus strains have been responsible for"/>
  <result pre="Although most people infected with SARS-CoV2 experience mild to moderate" exact="respiratory" post="symptoms and recover with supportive care, certain hosts (even"/>
  <result pre="intervention in these high-risk patients may provide a means to" exact="disease" post="amelioration and potentially expedited recovery, although to date no"/>
  <result pre="existing drugs and develop new therapies able to halt progressive" exact="disease" post="that leads to respiratory failure and death. Here, we"/>
  <result pre="new therapies able to halt progressive disease that leads to" exact="respiratory" post="failure and death. Here, we explore how we can"/>
  <result pre="in some hematopoietic cells, including monocytes and macrophages [3]. Direct" exact="diffuse" post="alveolar damage due to viral targeting of the human"/>
  <result pre="monocytes and macrophages [3]. Direct diffuse alveolar damage due to" exact="viral" post="targeting of the human respiratory tract epithelium via ACE2"/>
  <result pre="diffuse alveolar damage due to viral targeting of the human" exact="respiratory" post="tract epithelium via ACE2 receptors may lead to a"/>
  <result pre="in the host, which can result in the development of" exact="acute" post="respiratory failure and ultimately, in some cases, death. Decade-long"/>
  <result pre="the host, which can result in the development of acute" exact="respiratory" post="failure and ultimately, in some cases, death. Decade-long structural"/>
  <result pre="some cases, death. Decade-long structural studies on SARS-CoV postulate that" exact="viral" post="receptor recognition is one of the most important determinants"/>
  <result pre="[4]. Recently, a cohort of 21 patients with confirmed COVID-19" exact="infection" post="and severe disease showed markedly elevated blood levels of"/>
  <result pre="cohort of 21 patients with confirmed COVID-19 infection and severe" exact="disease" post="showed markedly elevated blood levels of cytokines and chemokines"/>
  <result pre="elevated blood levels of cytokines and chemokines that may predict" exact="disease" post="severity [5]. This virus-induced exaggerated host immune response is"/>
  <result pre="1918 influenza pandemic and also described with SARS and MERS" exact="infections" post="[6]. Early clinical reports of malaise, high fever, chills,"/>
  <result pre="clinical reports of malaise, high fever, chills, anosmia, dysgeusia and" exact="hypoxia" post="combined with biochemical markers associated with inflammation and hypercoagulable"/>
  <result pre="(IL)-6, high C-reactive protein and soluble CD25 suggest that SARS-CoV-2" exact="infection" post="may trigger cytokine storm syndrome. This hyper-reactive cytokine release"/>
  <result pre="hematopoietic stem cell transplant (HCT) and cellular therapies: cytokine release" exact="syndrome" post="(CRS), immune reconstitution inflammatory syndrome (IRIS), and secondary hemophagocytic"/>
  <result pre="and cellular therapies: cytokine release syndrome (CRS), immune reconstitution inflammatory" exact="syndrome" post="(IRIS), and secondary hemophagocytic lymphohistiocytosis (sHLH). Inflammatory conditions associated"/>
  <result pre="cytokine release syndrome (CRS), immune reconstitution inflammatory syndrome (IRIS), and" exact="secondary" post="hemophagocytic lymphohistiocytosis (sHLH). Inflammatory conditions associated with cellular therapies"/>
  <result pre="release syndrome (CRS), immune reconstitution inflammatory syndrome (IRIS), and secondary" exact="hemophagocytic lymphohistiocytosis" post="(sHLH). Inflammatory conditions associated with cellular therapies Three prominent"/>
  <result pre="immune reconstitution inflammatory syndrome (IRIS), and secondary hemophagocytic lymphohistiocytosis (sHLH)." exact="Inflammatory" post="conditions associated with cellular therapies Three prominent immune dysregulation"/>
  <result pre="features of COVID-19 and other hyperimmune response syndromes. Table 1" exact="Fever" post="Hypoxia Hypotension Cytokine storm Cytopenias Ferritin Hypofibrinogenemia Organomegaly CRS"/>
  <result pre="COVID-19 and other hyperimmune response syndromes. Table 1 Fever Hypoxia" exact="Hypotension" post="Cytokine storm Cytopenias Ferritin Hypofibrinogenemia Organomegaly CRS + +"/>
  <result pre="syndromes. Table 1 Fever Hypoxia Hypotension Cytokine storm Cytopenias Ferritin" exact="Hypofibrinogenemia" post="Organomegaly CRS + + + + +/â€&quot; +/â€&quot; +/â€&quot;"/>
  <result pre="(CAR)-T cell therapy and other immune therapies including but not" exact="limited" post="to anti-thymocyte globulin (ATG) rituximab, alemtuzumab and nivolumab. CRS"/>
  <result pre="CRS and neurotoxicity, consensus recommendations were recently implemented by the" exact="American" post="Society for Transplantation and Cellular Therapy [9] (Table 3)."/>
  <result pre="few days to weeks. CRS manifests with fever, tachycardia, hypotension," exact="respiratory" post="distress or hypoxemia and is associated with elevated circulating"/>
  <result pre="the clinical picture. Other laboratory findings are variable and reflect" exact="systemic" post="inflammation. sHLH/macrophage activation syndrome (MAS) is a syndrome of"/>
  <result pre="laboratory findings are variable and reflect systemic inflammation. sHLH/macrophage activation" exact="syndrome" post="(MAS) is a syndrome of excessive inflammation and tissue"/>
  <result pre="and reflect systemic inflammation. sHLH/macrophage activation syndrome (MAS) is a" exact="syndrome" post="of excessive inflammation and tissue destruction with overlapping features"/>
  <result pre="of CRS. In adults, sHLH is most commonly triggered by" exact="viral" post="infections. sHLH is characterized by T-cell-mediated inflammation, fulminant cytokine"/>
  <result pre="cytokine profile suggestive of HLH/MAS resolve with CRS resolution; therefore," exact="primary" post="amelioration of CRS with targeted cytokine biologics may be"/>
  <result pre="pharmacotherapies [10]. A retrospective study of COVID-19 patients found that" exact="elevated serum" post="ferritin and IL-6 correlated with increased mortality [2]. Table"/>
  <result pre="ferritin and IL-6 correlated with increased mortality [2]. Table 3" exact="American" post="Society for Transplantation and Cellular Therapy CAR-T-related CRS consensus"/>
  <result pre="consensus grading. Table 3 CRS parameter Grade 1 Grade 2" exact="Grade 3" post="Grade 4 Fevera Temperature â‰¥38Â°C Temperature â‰¥38Â°C Temperature â‰¥38Â°C"/>
  <result pre="Fevera Temperature â‰¥38Â°C Temperature â‰¥38Â°C Temperature â‰¥38Â°C Temperature â‰¥38Â°C With" exact="Hypotension" post="None Not requiring vasopressors Requiring a vasopressor with or"/>
  <result pre="grade is determined by the more severe event: hypotension or" exact="hypoxia" post="not attributable to any other cause. For example, a"/>
  <result pre="patient with temperature of 39.5Â°C, hypotension requiring one vasopressor, and" exact="hypoxia" post="requiring low-flow nasal cannula is classified as grade 3"/>
  <result pre="&amp;gt;6 L/min. Table 2 HLH diagnostic criteria. Table 2 HLH" exact="Fever" post="&amp;gt;38.5 Splenomegaly Cytopenia in at least 2 lineages (Hb"/>
  <result pre="2 lineages (Hb &amp;lt;9 g/dL, platelets &amp;lt;100Â 000/mm3, ANC &amp;lt;1000/mm3)" exact="Hypertriglyceridemia" post="(&amp;gt;265 mg/dL) and/or hypofibrinogenemia (&amp;lt;150 mg/dL) Hemophagocytosis in bone"/>
  <result pre="or liver Low or absent NK activity Ferritin &amp;gt;500 ng/mL" exact="Elevated" post="soluble CD25 (soluble IL-2 receptor alpha) 2SD above age-adjusted"/>
  <result pre="to make the diagnosis of HLH IRIS is another hyperinflammatory" exact="syndrome" post="with pathogenesis dependent on CD4+ T cells, proinflammatory cytokines,"/>
  <result pre="innate immune cells. IRIS is a phenomenon described in human" exact="immunodeficiency" post="virus (HIV) patients with severe lymphopenia and underlying opportunistic"/>
  <result pre="phenomenon described in human immunodeficiency virus (HIV) patients with severe" exact="lymphopenia" post="and underlying opportunistic infections, occurring during immune recovery upon"/>
  <result pre="human immunodeficiency virus (HIV) patients with severe lymphopenia and underlying" exact="opportunistic infections," post="occurring during immune recovery upon initiation of antiretrovirals and"/>
  <result pre="antiretrovirals and presenting as worsened clinical manifestations of a preexisting" exact="infection" post="or unmasking of a clinically silent infection [11]. Another"/>
  <result pre="of a preexisting infection or unmasking of a clinically silent" exact="infection" post="[11]. Another condition in which antimicrobial treatment may trigger"/>
  <result pre="Another condition in which antimicrobial treatment may trigger IRIS is" exact="Whipple's disease," post="a chronic infection due to Tropheryma whipplei that develops"/>
  <result pre="which antimicrobial treatment may trigger IRIS is Whipple's disease, a" exact="chronic" post="infection due to Tropheryma whipplei that develops in immunologically"/>
  <result pre="antimicrobial treatment may trigger IRIS is Whipple's disease, a chronic" exact="infection" post="due to Tropheryma whipplei that develops in immunologically susceptible"/>
  <result pre="pathogenesis of IRIS. This implies that independent of the causal" exact="infectious" post="agent, IRIS may possibly emerge in those carrying a"/>
  <result pre="should be undertaken to identify the predisposing dysfunctional immune condition." exact="Multiple" post="pathogens cause IRIS, which can manifest systemically or localize"/>
  <result pre="entirely understood [14]. The harmful effect of immune response to" exact="viral" post="triggers on immunosuppressed patients who experience IRIS with immune"/>
  <result pre="also been well described in the allogeneic HCT literature [15]." exact="Respiratory" post="viruses have been suggested to play a role in"/>
  <result pre="shared therapeutic interventions. CCLÂ =Â chemokine ligand, COVID-19Â =Â coronavirus" exact="disease" post="2019, CRPÂ =Â C-reactive protein, CRSÂ =Â Cytokine release"/>
  <result pre="=Â interleukin, IPÂ =Â induced protein, IRISÂ =Â Immune Reconstitution" exact="Inflammatory" post="Syndrome, MCPÂ =Â monocyte chemoattractant protein, MIPÂ =Â macrophage"/>
  <result pre="induced protein, IRISÂ =Â Immune Reconstitution Inflammatory Syndrome, MCPÂ =Â" exact="monocyte" post="chemoattractant protein, MIPÂ =Â macrophage inflammatory protein, PDGFÂ =Â"/>
  <result pre="macrophage inflammatory protein, PDGFÂ =Â Platelet-derived growth factor, sHLHÂ =Â" exact="Secondary" post="hemophagocytic lymphohistiocytosis, TNF- Î±Â =Â tumor necrosis factor Î±,"/>
  <result pre="inflammatory protein, PDGFÂ =Â Platelet-derived growth factor, sHLHÂ =Â Secondary" exact="hemophagocytic lymphohistiocytosis," post="TNF- Î±Â =Â tumor necrosis factor Î±, VEGFÂ =Â"/>
  <result pre="growth factor, sHLHÂ =Â Secondary hemophagocytic lymphohistiocytosis, TNF- Î±Â =Â" exact="tumor" post="necrosis factor Î±, VEGFÂ =Â vascular endothelial growth factor."/>
  <result pre="lymphohistiocytosis, TNF- Î±Â =Â tumor necrosis factor Î±, VEGFÂ =Â" exact="vascular" post="endothelial growth factor. References: Huang. Lancet 2020 (COVID-19); Brudno."/>
  <result pre="vascular endothelial growth factor. References: Huang. Lancet 2020 (COVID-19); Brudno." exact="Blood" post="2019 (CAR-T); Gopal. Eur Resp Review 2017 (IRIS); Schulert."/>
  <result pre="receptors by tocilizumab leads to a reduction in cytokine and" exact="acute" post="phase reactant production. IL-6 is a pleotropic cytokine with"/>
  <result pre="upon a tissue injury but also from skeletal muscle, smooth" exact="muscle" post="in blood vessels, adipocytes and, notably, by lung epithelial"/>
  <result pre="tissue injury but also from skeletal muscle, smooth muscle in" exact="blood vessels," post="adipocytes and, notably, by lung epithelial cells [18]. It"/>
  <result pre="smooth muscle in blood vessels, adipocytes and, notably, by lung" exact="epithelial" post="cells [18]. It could be hypothesized that myalgias, microthrombi"/>
  <result pre="the release of prostaglandin E2 (PGE2). Tocilizumab is indicated for" exact="adult" post="patients with autoimmune disorders such as rheumatoid arthritis and"/>
  <result pre="prostaglandin E2 (PGE2). Tocilizumab is indicated for adult patients with" exact="autoimmune" post="disorders such as rheumatoid arthritis and was approved by"/>
  <result pre="is indicated for adult patients with autoimmune disorders such as" exact="rheumatoid arthritis" post="and was approved by the U.S. Food and Drug"/>
  <result pre="indicated for adult patients with autoimmune disorders such as rheumatoid" exact="arthritis" post="and was approved by the U.S. Food and Drug"/>
  <result pre="in combination with corticosteroids. In a study of 40 hospitalized" exact="symptomatic" post="COVID-19 patients, the median IL-6 was reported 27.1 pg/mL"/>
  <result pre="was reported 27.1 pg/mL (range 0â€&quot;430 pg/mL). The risk of" exact="respiratory" post="failure for patients with IL-6 levels of â‰¥80 pg/ml"/>
  <result pre="92% and thus 22 times higher compared with patients with" exact="lower" post="IL-6 levels. After reaching an IL-6 value of 80"/>
  <result pre="IL6 (pg/ml) 37 27.1 (0â€&quot;430) 19.6 (0â€&quot;76.5) 121 (19.2â€&quot;430) 0.000012" exact="Platelet" post="count (G/ml) 40 165 (88â€&quot;440) 186 (88â€&quot;334) 160 (1â€&quot;440)"/>
  <result pre="blood cell count. The rapid clinical stabilization frequently seen after" exact="systemic" post="tocilizumab administration to CRS patients strongly implicates a cytokine"/>
  <result pre="IL-22 and dominated by IL-6, in the pathophysiology of the" exact="syndrome" post="[9]. The median time from the onset of CRS"/>
  <result pre="related to clinical decline in COVID-19 patients who progress to" exact="respiratory" post="failure. Given the similarities between CRS and COVID-19 hypercytokinemia"/>
  <result pre="IL-6 signaling in the pathophysiology of cytokine-driven hyperinflammatory syndromes [22]." exact="Severe" post="COVID-19 cases may benefit from IL-6 pathway inhibition given"/>
  <result pre="and efficacy when used with standard of care in hospitalized" exact="adult" post="patients with severe COVID-19 and in a phase II"/>
  <result pre="after administration of tocilizumab, contributing to an increased incidence of" exact="neurotoxicity" post="[20,23]. This does not seem to be a concern"/>
  <result pre="in patients with hyperinflammation, without increased adverse events [24]. Currently," exact="Swedish" post="Orphan Biovitrum has an open-label, multicenter clinical trial evaluating"/>
  <result pre="storm; however, correlation with the serum levels of IL-1 and" exact="disease" post="severity has not been described for COVID-19 patients. The"/>
  <result pre="potent and selective JAK inhibitors approved for indications such as" exact="rheumatoid arthritis" post="and myelofibrosis. All three are powerful anti-inflammatories that, as"/>
  <result pre="and selective JAK inhibitors approved for indications such as rheumatoid" exact="arthritis" post="and myelofibrosis. All three are powerful anti-inflammatories that, as"/>
  <result pre="of six patients who were receiving the drug for Waldenstrom's" exact="macroglobulinemia" post="and became ill with COVID-19 was recently reported. The"/>
  <result pre="BTK-inhibition may provide protection against lung injury and even improve" exact="pulmonary" post="function in hypoxic patients with COVID-19 [27]. Convalescent Plasma"/>
  <result pre="stabilized form of the spike (S) protein of SARS-CoV-2. The" exact="primary" post="objective of the study is to evaluate the safety"/>
  <result pre="mg on day 0, 500 mg on day 5) (https://www.clinicaltrials.gov/ct2/show/NCT04283461)." exact="Multiple" post="other vaccination studies are currently under development. Immunomodulation MSCs"/>
  <result pre="all immune cells, but also in cell populations, such as" exact="epithelial" post="cells, endothelial cells, fibroblasts, which take part in inflammatory"/>
  <result pre="has the highest number of MSC-treated patients suffering from (non-COVID)" exact="acute" post="respiratory distress syndrome (ARDS; nÂ =Â 40), that is,"/>
  <result pre="the highest number of MSC-treated patients suffering from (non-COVID) acute" exact="respiratory" post="distress syndrome (ARDS; nÂ =Â 40), that is, it"/>
  <result pre="number of MSC-treated patients suffering from (non-COVID) acute respiratory distress" exact="syndrome" post="(ARDS; nÂ =Â 40), that is, it showed that"/>
  <result pre="marrowâ€&quot;derived MSCs did not cause short- or long-term hemodynamic or" exact="respiratory" post="adverse events over a 60-day follow-up period. However, no"/>
  <result pre="was observed. This may be due to differences in the" exact="disease" post="severity within the study populations as well as low"/>
  <result pre="in Beijing administered BM-derived MSCs to seven patients with COVID-19" exact="pneumonia" post="with differing degrees of severity including one patient with"/>
  <result pre="differing degrees of severity including one patient with critically severe" exact="disease" post="requiring ICU care [27]. The MSCs were given as"/>
  <result pre="in 100 mL of saline at various times after initial" exact="symptomatic" post="presentation. The seven patients were categorized as critically severe"/>
  <result pre="inclusion and exclusion criteria, timing of MSC administration relative to" exact="disease" post="onset, comorbidities, the clinical course of each patient and"/>
  <result pre="cytomegalovirus (CMV), Epstein-Barr virus, adenovirus,[51], [52], [53], [54], [55] human" exact="herpes" post="virus (HHV)-6, BK polyomavirus (BK), [56] parainfluenza virus, [65]"/>
  <result pre="parainfluenza virus, [65] Zika virus, [57] mycobacteria, [58] norovirus, [59]" exact="herpes" post="simplex virus (HSV-1),[60] HIV [61] and others. Of these,"/>
  <result pre="killer (NK) cells are lymphocytes that recognize targets via the" exact="absence of" post="ligands such as HLA and a complex array of"/>
  <result pre="shown promise in a study of patients with CD19-positive nonâ€&quot;Hodgkin's" exact="lymphoma" post="or chronic lymphocytic leukemia. Recently, the FDA granted investigators"/>
  <result pre="promise in a study of patients with CD19-positive nonâ€&quot;Hodgkin's lymphoma" exact="or chronic" post="lymphocytic leukemia. Recently, the FDA granted investigators from the"/>
  <result pre="in a study of patients with CD19-positive nonâ€&quot;Hodgkin's lymphoma or" exact="chronic" post="lymphocytic leukemia. Recently, the FDA granted investigators from the"/>
  <result pre="a study of patients with CD19-positive nonâ€&quot;Hodgkin's lymphoma or chronic" exact="lymphocytic leukemia." post="Recently, the FDA granted investigators from the biotechnology company"/>
  <result pre="clinical data of the NK cell product CYNK-001, there is" exact="limited" post="public information about the efficacy of CYNK-001 or other"/>
  <result pre="shown in a range of preclinical studies, including those of" exact="acute" post="lung injury, to be as effective as the parent"/>
  <result pre="themselves [40]. However, there are several issues including but not" exact="limited" post="to source, isolation and purification approaches, manufacturing consistency and"/>
  <result pre="is likely premature to consider use of EVs for COVID-19" exact="respiratory" post="disease. Corticosteroids Evidence in patients with SARS and MERS"/>
  <result pre="administration of corticosteroids did not influence mortality but rather delayed" exact="viral" post="clearance [42]. Moreover, current interim guidance from the World"/>
  <result pre="from the World Health Organization on clinical management of severe" exact="acute" post="respiratory infection when novel coronavirus infection is suspected advises"/>
  <result pre="the World Health Organization on clinical management of severe acute" exact="respiratory" post="infection when novel coronavirus infection is suspected advises against"/>
  <result pre="World Health Organization on clinical management of severe acute respiratory" exact="infection" post="when novel coronavirus infection is suspected advises against the"/>
  <result pre="clinical management of severe acute respiratory infection when novel coronavirus" exact="infection" post="is suspected advises against the use of corticosteroids unless"/>
  <result pre="activity The combination of two antiviral molecules (lopinavir, a human" exact="immunodeficiency" post="virus type 1 aspartate protease inhibitor, plus ritonavir, an"/>
  <result pre="combination of two antiviral molecules (lopinavir, a human immunodeficiency virus" exact="type 1" post="aspartate protease inhibitor, plus ritonavir, an inhibitor of the"/>
  <result pre="has proved unfruitful compared with standard of care in an" exact="adult" post="cohort of hospitalized patients with severe SARS-CoV-2 pneumonia [44]."/>
  <result pre="in an adult cohort of hospitalized patients with severe SARS-CoV-2" exact="pneumonia" post="[44]. Therefore, further antiviral agents have been proposed. Hydroxychloroquine"/>
  <result pre="and; impair complement-dependent antigen-antibody reactions. Chloroquine has been used for" exact="malaria" post="treatment and chemoprophylaxis and hydroxychloroquine is used for treatment"/>
  <result pre="and chemoprophylaxis and hydroxychloroquine is used for treatment of several" exact="autoimmune" post="conditions including rheumatoid arthritis. Both drugs have in vitro"/>
  <result pre="hydroxychloroquine is used for treatment of several autoimmune conditions including" exact="rheumatoid arthritis." post="Both drugs have in vitro activity against coronaviruses, with"/>
  <result pre="relatively higher potency against SARS-CoV-2 [45]. On the basis of" exact="limited" post="in vitro and anecdotal data, chloroquine or hydroxychloroquine administered"/>
  <result pre="data are available. Remdesivir is an investigational antiviral which blocks" exact="viral" post="replication by inhibiting RNA synthesis [46]. It has broad"/>
  <result pre="RNA synthesis [46]. It has broad antiviral activity that inhibits" exact="viral" post="replication through premature termination of RNA transcription and has"/>
  <result pre="3 randomized open-label trials (https://clinicaltrials.gov/ct2/show/NCT04292899 and https://clinicaltrials.gov/ct2/show/NCT04292730) or on an" exact="uncontrolled" post="compassionate use basis. In a cohort of patients hospitalized"/>
  <result pre="drugsâ€™ safety and effectiveness in randomized, controlled trials remains the" exact="primary" post="tool for protecting the public from drugs that are"/>
  <result pre="a pandemic of unprecedented modern proportions. COVID-19 ranges from mild" exact="viral" post="illness in most hosts to life-threatening disease in a"/>
  <result pre="ranges from mild viral illness in most hosts to life-threatening" exact="disease" post="in a subset of patients who develop hyperimmune inflammatory"/>
  <result pre="studies aimed at unraveling the immune response in lung and" exact="peripheral" post="blood will aid in understanding the risk of developing"/>
  <result pre="on preexisting conditions and not the virus itself. In the" exact="absence of" post="FDA- and European Medicines Agencyâ€&quot;approved treatments for COVID-19, management"/>
  <result pre="Experiences derived from therapeutics employed for the treatment of complications" exact="secondary" post="to immunotherapies, such as CAR-T, bispecific monoclonal antibodies and"/>
  <result pre="exercised to avoid the use of unproven therapeutics based on" exact="limited" post="data from poorly conducted clinical trials and/or observational data"/>
  <result pre="a definite answer. References References 1National Institute of Allergy and" exact="Infectious" post="Disease. COVID-19, MERS &amp;amp; SARS. Updated April 6, 2020."/>
  <result pre="and consequences of cytokine storm and immunopathologySemin Immunopathol39201752953928466096 3MooreB.J.B.JuneC.H.Cytokine release" exact="syndrome" post="in severe COVID-19Science368202047347432303591 4Wan S., Fang W., Zheng Y.,"/>
  <result pre="Engl J Med35220051839184215872196 7ParkJ.H.RiviereI.GonenM.WangX.SenechalB.CurranK.J.Long-term follow-up of CD19 CAR therapy in" exact="acute" post="lymphoblastic leukemiaN Engl J Med378201844945929385376 8MaudeS.L.LaetschT.W.BuechnerJ.RivesS.BoyerM.BittencourtH.Tisagenlecleucel in children and"/>
  <result pre="leukemiaN Engl J Med378201843944829385370 9LeeD.W.SantomassoB.D.LockeF.L.GhobadiA.TurtleC.J.BrudnoJ.N.ASTCT consensus grading for cytokine release" exact="syndrome" post="and neurologic toxicity associated with immune effector cellsBiol Blood"/>
  <result pre="release syndrome and neurologic toxicity associated with immune effector cellsBiol" exact="Blood" post="Marrow Transplant25201962563830592986 10TeacheyD.T.LaceyS.F.ShawP.A.MelenhorstJ.J.MaudeS.L.FreyN.Identification of predictive biomarkers for cytokine release"/>
  <result pre="Blood Marrow Transplant25201962563830592986 10TeacheyD.T.LaceyS.F.ShawP.A.MelenhorstJ.J.MaudeS.L.FreyN.Identification of predictive biomarkers for cytokine release" exact="syndrome" post="after chimeric antigen receptor T-cell therapy for acute lymphoblastic"/>
  <result pre="cytokine release syndrome after chimeric antigen receptor T-cell therapy for" exact="acute" post="lymphoblastic leukemiaCancer Discov6201666467927076371 11BoulougouraA.SeretiI.HIV infection and immune activation: the"/>
  <result pre="antigen receptor T-cell therapy for acute lymphoblastic leukemiaCancer Discov6201666467927076371 11BoulougouraA.SeretiI.HIV" exact="infection" post="and immune activation: the role of coinfectionsCurr Opin HIV"/>
  <result pre="pathogenesis and treatmentLancet Infect Dis8200817919018291339 13MoosV.FeurleG.E.SchinnerlingK.GeelhaarA.FriebelJ.AllersK.Immunopathology of immune reconstitution inflammatory" exact="syndrome" post="in Whipple's diseaseJ Immunol19020132354236123365082 14GopalR.RapakaR.R.KollsJ.K.Immune reconstitution inflammatory syndrome associated"/>
  <result pre="reconstitution inflammatory syndrome in Whipple's diseaseJ Immunol19020132354236123365082 14GopalR.RapakaR.R.KollsJ.K.Immune reconstitution inflammatory" exact="syndrome" post="associated with pulmonary pathogensEur Respir Rev261432017160042 15VersluysA.B.BoelensJ.J.Morbidity and mortality"/>
  <result pre="in Whipple's diseaseJ Immunol19020132354236123365082 14GopalR.RapakaR.R.KollsJ.K.Immune reconstitution inflammatory syndrome associated with" exact="pulmonary" post="pathogensEur Respir Rev261432017160042 15VersluysA.B.BoelensJ.J.Morbidity and mortality associated with respiratory"/>
  <result pre="with pulmonary pathogensEur Respir Rev261432017160042 15VersluysA.B.BoelensJ.J.Morbidity and mortality associated with" exact="respiratory" post="virus infections in allogeneic hematopoietic cell transplant: too little"/>
  <result pre="pathogensEur Respir Rev261432017160042 15VersluysA.B.BoelensJ.J.Morbidity and mortality associated with respiratory virus" exact="infections" post="in allogeneic hematopoietic cell transplant: too little defense or"/>
  <result pre="or harmful immunity?Front Microbiol92018279530519222 16VersluysB.BieringsM.Luc MurkJ.Luc MurkJ.WolfsT.LindemansC.vd EntK.Infection with a" exact="respiratory" post="virus before hematopoietic cell transplantation is associated with alloimmune-mediated"/>
  <result pre="Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppressionLancet39520201033103432192578 18CrestaniB.CornilletP.DehouxM.RollandC.GuenounouM.AubierM.Alveolar" exact="type II" post="epithelial cells produce interleukin-6 in vitro and in vivo."/>
  <result pre="COVID-19: consider cytokine storm syndromes and immunosuppressionLancet39520201033103432192578 18CrestaniB.CornilletP.DehouxM.RollandC.GuenounouM.AubierM.Alveolar type II" exact="epithelial" post="cells produce interleukin-6 in vitro and in vivo. Regulation"/>
  <result pre="macrophage secretory productsJ Clin Invest9419947317408040328 19HeroldT.JurinovicV.ArnreichC.HellmuthJ.C.von Bergwelt-BaildonM.KleinM.Level of IL-6 predicts" exact="respiratory" post="failure in hospitalized symptomatic COVID-19 patients [preprint]MEDRXIV202010.1101/2020.04.01.20047381 20ChenF.TeacheyD.T.PequignotE.FreyN.PorterD.MaudeS.L.Measuring IL-6"/>
  <result pre="Invest9419947317408040328 19HeroldT.JurinovicV.ArnreichC.HellmuthJ.C.von Bergwelt-BaildonM.KleinM.Level of IL-6 predicts respiratory failure in hospitalized" exact="symptomatic" post="COVID-19 patients [preprint]MEDRXIV202010.1101/2020.04.01.20047381 20ChenF.TeacheyD.T.PequignotE.FreyN.PorterD.MaudeS.L.Measuring IL-6 and sIL-6R in serum"/>
  <result pre="Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced" exact="Severe" post="or Life-Threatening Cytokine Release SyndromeThe Oncologist23201894394729622697 22KangS.TanakaT.NarazakiM.KishimotoT.Targeting interleukin-6 signaling"/>
  <result pre="administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with" exact="rheumatoid arthritis" post="and Castleman diseaseBlood11220083959396418784373 24ShakooryB.CarcilloJ.A.ChathamW.W.AmdurR.L.ZhaoH.DinarelloC.A.Interleukin-1 receptor blockade is associated with"/>
  <result pre="of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid" exact="arthritis" post="and Castleman diseaseBlood11220083959396418784373 24ShakooryB.CarcilloJ.A.ChathamW.W.AmdurR.L.ZhaoH.DinarelloC.A.Interleukin-1 receptor blockade is associated with"/>
  <result pre="in the recovery stage by single-cell sequencingCell Discovery620203110.1038/s41421-020-0168-932377375 26AhmedA.MerrillS.A.AlsawahF.BockenstedtP.CampagnaroE.DevataS.Ruxolitinib in" exact="adult" post="patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot"/>
  <result pre="stage by single-cell sequencingCell Discovery620203110.1038/s41421-020-0168-932377375 26AhmedA.MerrillS.A.AlsawahF.BockenstedtP.CampagnaroE.DevataS.Ruxolitinib in adult patients with" exact="secondary" post="haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trialLancet Haematol62019e630e63731537486 27TreonS.P.CastilloJ.SkarbnikA.P.SoumeraiL.D.GhobrialI.M.GuerreraM.L.The"/>
  <result pre="single-centre, pilot trialLancet Haematol62019e630e63731537486 27TreonS.P.CastilloJ.SkarbnikA.P.SoumeraiL.D.GhobrialI.M.GuerreraM.L.The BTK-inhibitor ibrutinib may protect against" exact="pulmonary" post="injury in COVID-19 infected patientsBlood13520201912191532302379 28ZhouB.ZhongN.GuanY.Treatment with convalescent plasma"/>
  <result pre="33MatthayM.A.CalfeeC.S.ZhuoH.ThompsonB.T.WilsonJ.G.LevittJ.E.Treatment with allogeneic mesenchymal stromal cells for moderate to severe" exact="acute" post="respiratory distress syndrome (START study): a randomised phase 2a"/>
  <result pre="with allogeneic mesenchymal stromal cells for moderate to severe acute" exact="respiratory" post="distress syndrome (START study): a randomised phase 2a safety"/>
  <result pre="mesenchymal stromal cells for moderate to severe acute respiratory distress" exact="syndrome" post="(START study): a randomised phase 2a safety trialLancet Respir"/>
  <result pre="F.E., Rocco P.R.M., Weiss D.J.Current status of cell-based therapies for" exact="respiratory" post="virus infections [published online ahead of prin April 7,"/>
  <result pre="P.R.M., Weiss D.J.Current status of cell-based therapies for respiratory virus" exact="infections" post="[published online ahead of prin April 7, 2020]. Eur"/>
  <result pre="badCurr Opin Cell Biol352015697726001269 40ShahT.G.PredescuD.PredescuS.Mesenchymal stem cells-derived extracellular vesicles in" exact="acute" post="respiratory distress syndrome: a review of current literature and"/>
  <result pre="Opin Cell Biol352015697726001269 40ShahT.G.PredescuD.PredescuS.Mesenchymal stem cells-derived extracellular vesicles in acute" exact="respiratory" post="distress syndrome: a review of current literature and potential"/>
  <result pre="2019-nCoV lung injuryLancet395202047347532043983 43World Health Organization. Clinical management of severe" exact="acute" post="respiratory infection when novel coronavirus (nCoV) infection is suspected."/>
  <result pre="lung injuryLancet395202047347532043983 43World Health Organization. Clinical management of severe acute" exact="respiratory" post="infection when novel coronavirus (nCoV) infection is suspected. 27"/>
  <result pre="injuryLancet395202047347532043983 43World Health Organization. Clinical management of severe acute respiratory" exact="infection" post="when novel coronavirus (nCoV) infection is suspected. 27 May"/>
  <result pre="management of severe acute respiratory infection when novel coronavirus (nCoV)" exact="infection" post="is suspected. 27 May 2020. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected 44CaoB.WangY.WenD.LiuW.WangJ.FanG.A trial of"/>
  <result pre="Sims, Graham R.L., Sheahan T.P., Lu X., et al. Coronavirus" exact="susceptibility to" post="the antiviral remdesivir (GS-5734) is mediated by the viralpolymerase"/>
  <result pre="Med121020061160116616998485 53HanleyP.J.MelenhorstJ.J.NikiforowS.ScheinbergP.BlaneyJ.W.Demmler-HarrisonG.CMV-specific T cells generated from naive T cells recognize" exact="atypical" post="epitopes and may be protective in vivoSci Transl Med72852015285ra63"/>
  <result pre="populations in cord blood and will target a range of" exact="viral" post="epitopesBlood114920091958196719443656 56GerdemannU.KeirnanJ.M.KatariU.L.YanagisawaR.ChristinA.S.HuyeL.E.Rapidly generated multivirus-specific cytotoxic T lymphocytes for the"/>
  <result pre="multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of" exact="viral" post="infectionsMol Ther20820121622163222801446 57HanajiriR.SaniG.M.HanleyP.J.SilveiraC.G.KallasE.G.KellerM.D.Generation of Zika virus-specific T cells from"/>
  <result pre="Be Expanded From Healthy Donors and Are Near Absent in" exact="Primary" post="Immunodeficiency DisordersFront Immunol10201962130984189 59HanajiriR.SaniG.M.SaundersD.HanleyP.J.ChopraA.MallalS.A.Generation of Norovirus-Specific T Cells From"/>
  <result pre="Expanded From Healthy Donors and Are Near Absent in Primary" exact="Immunodeficiency" post="DisordersFront Immunol10201962130984189 59HanajiriR.SaniG.M.SaundersD.HanleyP.J.ChopraA.MallalS.A.Generation of Norovirus-Specific T Cells From Human"/>
  <result pre="Norovirus-Specific T Cells From Human Donors With Extensive Cross-Reactivity to" exact="Variant" post="Sequences: Implications for ImmunotherapyJ Infect Dis2214202057858831562500 60MaC.K.ClancyL.DeoS.BlythE.MicklethwaiteK.P.GottliebD.J.Herpes simplex virus"/>
  <result pre="Variant Sequences: Implications for ImmunotherapyJ Infect Dis2214202057858831562500 60MaC.K.ClancyL.DeoS.BlythE.MicklethwaiteK.P.GottliebD.J.Herpes simplex virus" exact="type 1" post="(HSV-1) specific T-cell generation from HLA-A1- and HLA-A2-positive donors"/>
  <result pre="T Cell Bank within an Allogeneic Stem Cell Transplant ProgramBiol" exact="Blood" post="Marrow Transplant241220182433244230172015 65McLaughlinL.P.LangH.WilliamsE.WrightK.E.PowellA.CruzC.R.Human parainfluenza virus-3 can be targeted by"/>
  <result pre="Fondazione TIM. M.C. and J.J.B. acknowledge support of the NIH" exact="Cancer" post="Center Support Grant P30 CA008748. Declaration of Competing Interest"/>
  <result pre="honoraria: Novartis, Terumo, AstraZeneca; consulting or advisory role: Brammer Bio/ThermoFisher" exact="Viral" post="Vector services, Avectas, Immuneel, Ori Biotech and Vycellix. VB:"/>
 </snippets>
</snippetsTree>
